Trivedi, Palak J.

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 39

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

Murillo Perez, C. F., Ioannou, S., Hassanally, I., Trivedi, P. J., Corpechot, C., van der Meer, A. J., Lammers, W. J., Battezzati, P. M., Lindor, K. D., Nevens, F., et al. (2023) · Liver International

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 39

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 38

Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery

Abbas, N., Smith, R., Flack, S., Bains, V., Aspinall, R. J., Jones, R. L., Burke, L., Thorburn, D., Heneghan, M., Yeoman, A., et al. (2024) · JHEP Reports

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 31

Renaming primary biliary cirrhosis—clarity or confusion?

Trivedi, P. J., & Hirschfield, G. M. (2015) · Nature Reviews Gastroenterology & Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 22

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results

Levy, C., Trivedi, P. J., Kowdley, K. V., Gordon, S. C., Bowlus, C. L., Londoño, M. C., Hirschfield, G. M., Gulamhusein, A., Lawitz, E. J., Vierling, J. M., et al. (2026) · American Journal of Gastroenterology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 20

Risk stratification in primary sclerosing cholangitis: it's time to move on from replicating imperfection and break the glass ceiling

Trivedi, P. J. (2019) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 14

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid

Dunn, S., Evans, L., Kennedy, C., Wafer, R., Moody, S., Wolstenhulme, F., Burton, E., Konkoth, A. B., Fisher, H., Chadwick, T., et al. (2026) · BMJ Open

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 0